BI 409306

Drug Profile

BI 409306

Alternative Names: BI409306; SUB 166499

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antidementias
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Psychotic disorders; Schizophrenia
  • Phase I Cognition disorders

Most Recent Events

  • 28 Nov 2017 Boehringer Ingelheim plans a phase III trial in Schizophrenia (Adjunctive therapy) (EudraCT2017-002369-23) (NCT03351244) (Trial profile 700290733)
  • 09 Oct 2017 Boehringer Ingelheim completes a phase II trial for Alzheimer's disease (Treatment naive) in USA, Canada, United Kingdom, Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Portugal and Spain (PO) (NCT02240693)
  • 29 Sep 2017 Phase-II clinical trials in Psychotic disorders (In adolescents, In adults) in USA (PO) (NCT03230097)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top